ClinicalTrials.gg
RecruitingNCT03810573Updated Oct 15, 2026

Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis

An interventional study of NB1 in Degenerative Disc Disease and Spondylolisthesis, sponsored by Bone Biologics Corp. Recruiting at 2 sites in Australia. Open to participants aged 17 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Bone Biologics Corp · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 15, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
17 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Intervertebral Disc Degeneration with a site in Australia — 4 open to participants now, 5 under way, none of them phase 3. Intervertebral Disc Degeneration · Australia.

Planned enrollment
10th of 12
30 · median 60
Started
2024
with 2 others
No phase
6 of 13
2 open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Bone Biologics Corp

Among the 13 studies in Intervertebral Disc Degeneration with a site in Australia, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 with no phase, and was the 8th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

4 of the 13 studies in Intervertebral Disc Degeneration with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 17 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Intervertebral Disc Degeneration with a site in Australia, or all of them as a file.
02

Study summary

The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion.

It is estimated that up to 30 participants will be enrolled in approximately 3 clinical sites. During baseline and follow-up assessments, patients will be asked to undergo x-rays and CT scans; adverse events and immunology will be collected, and; participants will be requested to complete participant questionnaires regarding quality of life, pain and function.

03

Conditions studied

  • Degenerative Disc Disease
  • Spondylolisthesis
04

Who can participate

Ages eligible
17 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of degenerative disc disease
  • Up to Grade I spondylolisthesis
  • Eligible to undergo a single vertebral level spine fusion (L2 to S1)

Exclusion criteria

Exclusion Criteria:

  • Previous spinal instrumentation or previous interbody fusion procedure at the involved level
  • Grade II or greater spondylolisthesis
  • Systemic or local infection at the site of surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    NB1-1.5

    NB1 low dose

    Device: NB1

  • Experimental
    NB1-2.0

    NB1 high dose

    Device: NB1

  • No intervention
    Autograft

    Autograft

Interventions

  • DeviceNB1

    rhNELL-1/DBX

06

What researchers measure

Primary outcomes

  1. Fusion

    Defined by an independent (blinded to treatment) radiological assessment as less than five degrees angular vertebral motion, less than three millimeters of translational movement and evidence of bridging bone between the involved vertebral endplates based on x-rays at 12 months after surgery

    Time frame: 12 months

Secondary outcomes

  1. Removal, revision, or supplemental fixation

    Whether there was removal, revision or supplemental fixation of the graft material that required reoperation at the index level during the follow-up period of the study

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
  • Monash Medical Center
    Clayton, Victoria 3168, Australia
    Recruiting
    • Jeremy Kam, MD · Contact
    • Jeremy Kam, MD · Principal investigator
  • St Vincent Melbourne
    Fitzroy, Australia
    Recruiting
    • Terence Tan · Contact
    • Ternence Tan, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — As requested

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's planned 33 months is below that.

Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jun 2025 → Dec 2026 and completion Jun 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 18, 2019
StartActual
Mar 1, 2024
Primary completionEst.
Dec 31, 2026was Jun 2025
CompletionEst.
Dec 1, 2028was Jun 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • St George Hospital · Kogarah, Australia
Oct 15, 2026
Primary completion
Jun 1, 2025→Dec 31, 2026
Oct 15, 2026
Study completion
Jun 1, 2026→Dec 1, 2028
Oct 15, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Monash Medical Center · Clayton, AustraliaContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • St Vincent Melbourne · Fitzroy, AustraliaContact person changed (no phone or email listed)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site removed
    Show 1 removed
    • St George Hospital · Kogarah, Australia
    Primary completion Jun 1, 2025→Dec 31, 2026
    Study completion Jun 1, 2026→Dec 1, 2028
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Monash Medical Center · Clayton, AustraliaContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • St Vincent Melbourne · Fitzroy, AustraliaContact person changed (no phone or email listed)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03810573
Lead sponsor
Bone Biologics Corp
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Mar 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Brent Atkinson, PhD
Contact
atkinsonbrent520@gmail.com
13035507866
Jeremy Kam, MD
principal investigator · Monash Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion